This decision is a further setback for Amgen in his attempts at Praluent, a Repatha competitor developed jointly by Sanofi and Regeneron.
In February, a jury had confirmed the validity of three of Amgen's five patents on Repatha, but Sanofi and Regeneron had filed motions for annulment.
Praluent is an injection treatment approved in 2015 by the FDA, the leading federal health authority in the United States. Amgen sued Sanofi and Regeneron in 2014 over the Praluent claiming it was violating his Repatha's patents.
(Jan Wolfe, Marc Angrand for French service)